First Berlin Equity Research GmbH’s Post

Die Kanzlei WEITNAUER Attorneys-at-Law and Tax Advisors hat einen Teil der Gesellschafter von Dynamic Biosensors | a Bruker company – darunter Bayern Kapital, KfW, Falk Strascheg Holding und BayBG Bayerische Beteiligungsgesellschaft mbH – beim Verkauf an Bruker Corporation (Nasdaq: BRKR), rechtlich beraten. Mehr zur #Transaktion lesen Sie im Beitrag! #Exit #Investing #PE #VC #VCMagazin #Bio

Through three quarters, we've seen increased investment across all Medtech and Healthtech verticals, and many new financing rounds across the LSI Alumni community. During Q3 this momentum continued to grow as we saw the LSI Alumni raise nearly $900M across 55+ deals in Q3 alone. Throughout 2024, LSI Alumni have collectively raised over $2 billion in total capital through 120+ deals. These achievements reflect not just the success of the LSI Alumni but also the momentum and innovation driving the Medtech industry as a whole. Congratulations to all those contributing to these milestones, pushing the boundaries of what's possible, and ultimately advancing patient care. There were over 50 LSI Alumni deals in Q3, so I can’t list them all, but here are a few call-outs: - Kneevoice Inc. (Gustavo De Greiff) // $1.25M Seed - Prana Thoracic (Joanna Nathan) // $3M Series A Extension - CorFlow (Paul Mead) // €44M Series B - NanoHive Medical (Patrick O.) // $7M Series C - WISE SpA (Luca Ravagnan) // €25M Series D - Magenta Medical Ltd. (David Israeli, MD) // $105M Later Stage View our spreadsheet with all the companies, deals, investors & more: https://lnkd.in/djUYnsMK

Why does Titan III Capital concentrate on multifamily housing in Ivy League Life Science Centers? We are a physician-owned company with decades of clinical and research experience. Because we and most of our investors spend our lives in this ecosystem, we essentially house ourselves or professionals exactly like us. The National Institue of Health NIH, increased funding by 7.3% which is the largest percentage increase in several years. UPenn historically has ranked fifth in receiving the most NIH funding. As most know, research drives development. For UPenn, cell therapy emerged from such grant support attracting private pharma investments measuring in the 100's of millions. With this, comes jobs and high earning professionals needing housing. This is where Titan III Capital fits in. We recognize the growth, industry, and importance of life science for our investors. Come learn more! titan3capital.com/webinar source: National Institutes of Health, CBRE Research, Q4 2023.

Mit Schwung von der #EntrepreneurshipNight2024 in die nächste Runde: Qubo, ChromeO und "A New Class of Abdominal Pain Medication", drei spin-offs der Universität Wien haben es auf die Shortlist für den renommierten S&B Award 2024 von brutkasten geschafft. 🏆 Bis zum 13. Mai können Sie auch Ihre Stimme abgeben. Weitere Informationen finden Sie unter univie innovation 👇 #innovation #univie

➖ Strategic Placement ➖ #Orthocell has today announced that it has completed a Company-led Strategic Placement to raise $3.5 million.   The Company welcomes prominent investors Mr Chris Ellison, Mr Rod Jones, Mr Michael Malone, the McCusker Family and the Merchant Biotech Fund, which significantly strengthens the Company’s share register.   With the strategic placement now complete, the Company is well funded to execute its global market expansion strategy and the pivotal US product registration for Remplir™, expected in Q1 CY24   Orthocell Chair, John Van Der Wielen, said:   “The support of these strategic investors is an endorsement of Orthocell’s science, business strategy and progress in commercialising its leading bone and nerve repair products, and the exciting outlook for the Company as it progresses approvals in new key jurisdictions like the US. The Board and I would like to welcome the new investors to the register.”   Read today’s ASX release 👉 https://lnkd.in/gg89rcai $OCC #biotech #regenerativemedicine #medicaldevice #healthcare #innovation #placement #ASX

📑 ⚕ Auf dem Weg zu einem deutschen Textkorpus für die Medizin: Vor fast genau einem Jahr hat das GeMTeX-Team seine Arbeiten aufgenommen. Im aktuellen MIRACUM DIFUTURE-Journal erfährst du, welche Meilensteine das GeMTeX-Projekt in diesem Jahr erreicht hat und welche Herausforderungen bewältigt werden müssen: 👉 https://lnkd.in/esjq_yJp Hintergrund: Die medizinische Versorgung kann sehr von Programmen natürlicher Sprachverarbeitung und #KI-basierten Sprachmodellen profitieren. So könnten beispielsweise Routineabläufe wie das Schreiben von Arztbriefen oder klinischen Berichten automatisiert werden. Für das Training derartiger Modelle sind große Mengen an verfügbaren Textdaten notwendig. Allerdings sind die meisten frei verwendbaren medizinsichen Texte in englischer Sprache verfasst. Hier setzt das GeMTeX-Projekt an: Das Ziel ist, deutschsprachige Texte aus der klinischen Versorgung so aufzubereiten, dass sie für das Training von KI-Modellen nutzbar sind. Dabei soll das größte Korpus an medizinsichen Texten in deutscher Sprache entstehen. Nicht nur die Patientenversorgung, auch die medizinsiche Forschung profitiert vom Ausbau und der Bereitstellung medizinischen Wissens. 🩺👩🔬👨🔬 Mehr dazu erfahrt hier auf den Seiten 48ff im aktuellen MIRACUM DIFUTURE-Journal! #medizininformatik #gemtex_mii #nlp #healthdata #healthresearch #medicalresearch #digitalisierung

The femtech industry is expected to reach $103 billion by 2030. Motivated by an explosion of companies dedicated to disrupting a historically underserved space, femtech companies are collecting valuable insights to power future developments. Our Partner and Director of the Life Sciences Practice Group, Katherine Rubino, and our Associate, Kasia Zebrowska-Trauben, discussed IP considerations for this emerging market in Inc. Magazine, highlighting the value of developing a robust IP strategy to secure funding. As more and more femtech companies enter the market, leaders will need to establish business objectives early on to protect their transformative innovations and create the most successful IP strategies. Read more advice about the ways IP can protect innovative breakthroughs in life sciences from Kasia and Katherine in Inc.: https://lnkd.in/gGnpQQ_h

So macht Forschungskommunikation Spass :-)

Was den Biotech-Markt attraktiv macht? Thomas Vorlicky, Geschäftsführer bei Medical Strategy - Biotech Investors sprach beim Fundview Boutiquen-Tag powered by Hauck Aufhäuser Lampe über Zukunftsaussichten sowie über das Bewertungsniveau der Branche und welche Therapiegebiete dabei zukunftsträchtig sind.     „Die Bewertungsniveaus sind historisch attraktiv“: Thomas Vorlicky gibt im Interview mit Oliver Howard spannende Einblicke und Antworten auf folgende Fragen:    ◾ Welche Zukunftsaussichten gibt es für den Biotech-Markt?  ◾ Wie sind die aktuellen Bewertungsniveaus?  ◾ Welche Therapiegebiete sind zukunftsträchtig?  ◾ Spielt das Thema KI im Biotech-Markt eine Rolle?  ◾ Ist ein möglicher Nebenwerte-Turnaround ein zusätzlicher Faktor? 🎬 Jetzt anschauen und mehr erfahren! https://lnkd.in/eWVffjGs #assetservicing #hauckaufhaeuserlampe #halprivatbank #biotech #investment #fonds #assets 

Did you know that costs for non-medical eye interventions range from ~€800 to €2,600 per eye? This week, we analysed 30 European optical healthcare businesses and gathered insights on how incumbents experience difficulties in scaling abroad organically due to legislative and regulatory barriers. The majority (>65%) of all identified players is sponsor-backed. The main drivers for interest are strong underlying market growth due to an ageing demographic as well as increased prevalence of eye defects caused by e.g. increased screen time. Furthermore, investors in eye clinic platforms are attracted by the ample opportunities for buy-and-build expansion. 21 Invest, Adagia Partners, Ares Management Corporation, Barings, BNP Paribas, Bpifrance, Buysse & Partners - Private Equity & Real Estate, Capricorn Ventures, Committed Capital, Earlybird Venture Capital, EQT Group, Eurazeo, G Square Healthcare Private Equity LLP, Gimv, GBL (Groupe Bruxelles Lambert), H2 Equity Partners (Amsterdam), KCE - Kaizaharra Corporación Empresarial, LRM, M80 Partners, MidEuropa, Montagu, Naxicap Partners, NORD Holding UBG mbH, Noshaq, PAI Partners, Qbic Fund | Venture Capital and Trilantic Europe are currently invested in European optical healthcare players. Interested? Read our full report: https://lnkd.in/edR8vgMw #origination #privateequity #fintech #finance #consulting #optics #myopia #healthcare #medtech #surgery #clinics